论文部分内容阅读
对299例晚期恶性胸腔积液、腹腔积液、浅表肿瘤及子宫颈癌患者用揽香烯乳进行了国内多中心前瞻性Ⅱ期临床研究。治疗恶性胸腔积液按200mg/m~2,腹腔积液按400mg/m~2,注射1～2次/周。治疗局部浅表病灶包括皮肤结节及子宫颈癌,则采用局部注射,25～50mg/次,1次/d,连用5～10d。结果表明,该制剂对恶性胸腔积液的疗效为74.8％,对恶性腹腔积液的疗效为75.0％;接受局部注射的患者,有效率为63.5％。本品无骨髓毒性,但有可被大多数患者耐受的胃肠道反应、发热和局部疼痛。
A multicenter prospective phase II clinical study of 299 patients with advanced malignant pleural effusions, peritoneal effusions, superficial tumors, and cervical cancers was conducted. Treatment of malignant pleural effusion 200mg/m~2, ascites fluid 400mg/m~2, injection 1~2 times/week. For the treatment of local superficial lesions including skin nodules and cervical cancer, local injections were used, 25 to 50 mg/time, once daily for 5 to 10 days. The results showed that the efficacy of the preparation was 74.8% for malignant pleural effusion, 75.0% for malignant peritoneal effusion, and 63.5% for patients receiving local injection. This product has no bone marrow toxicity, but it can be tolerated by most patients with gastrointestinal reactions, fever and local pain.